ICD-10-PCS · FY 2027
Deleted ICD-10-PCS Codes for FY 2027
Effective . 41 deleted codes in this release.
← All changes in FY 2027| Code | Description |
|---|---|
| 30233AZ | Transfusion of Embryonic Stem Cells into Peripheral Vein, Percutaneous Approach |
| 30243AZ | Transfusion of Embryonic Stem Cells into Central Vein, Percutaneous Approach |
| X2KB317 | Bypass Right Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7 |
| X2KC317 | Bypass Left Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7 |
| XD2 | New Technology, Gastrointestinal System, Monitoring |
| XD2G4V7 | Monitoring of Upper GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7 |
| XD2G8V7 | Monitoring of Upper GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7 |
| XD2H4V7 | Monitoring of Lower GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7 |
| XD2H8V7 | Monitoring of Lower GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7 |
| XRGA0R7 | Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7 |
| XRGA3R7 | Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7 |
| XRGA4R7 | Fusion of Thoracolumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7 |
| XRGB0R7 | Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7 |
| XRGB3R7 | Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7 |
| XRGB4R7 | Fusion of Lumbar Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7 |
| XRGC0R7 | Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7 |
| XRGC3R7 | Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7 |
| XRGC4R7 | Fusion of 2 or more Lumbar Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7 |
| XRGD0R7 | Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 7 |
| XRGD3R7 | Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 7 |
| XRGD4R7 | Fusion of Lumbosacral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7 |
| XW00X27 | Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7 |
| XW01397 | Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 |
| XW01X27 | Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7 |
| XW023X7 | Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7 |
| XW03367 | Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW03377 | Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW03387 | Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW033B7 | Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW04367 | Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW04377 | Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW04387 | Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW043B7 | Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW0DXR7 | Introduction of Fostamatinib into Mouth and Pharynx, External Approach, New Technology Group 7 |
| XW0G7R7 | Introduction of Fostamatinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 7 |
| XW0H7R7 | Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7 |
| XW133D7 | Transfusion of High-Dose Intravenous Immune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW133F8 | Transfusion of OTL-103 into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
| XW143D7 | Transfusion of High-Dose Intravenous Immune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XXE5XR7 | Measurement of Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure, New Technology Group 7 |
| XXE5XT7 | Measurement of Intracranial Arterial Flow, Whole Blood mRNA, New Technology Group 7 |